Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 237

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 237
---
 $
    -

    $
    51,097

(1)Dr. Manuso was appointed to our board of directors on October 18, 2024 in connection with the consummation of the Kintara Merger.

(2)Dr. List was appointed to our board of directors on October 18, 2024 in connection with the consummation of the Kintara Merger.

(3)Mr. Ng. was appointed to our board of directors on October 18, 2024 in connection with the consummation of the Kintara Merger.

(4)Mr. Hoffman served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and was subsequently appointed to our board of directors on October 18, 2024 in connection with the Kintara Merger.

(5)Mr. Toth served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and ceased serving on the board of directors in connection with the consummation of the Kintara Merger.

(6)Ms. Johnson served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and ceased serving on the board of directors in connection with the consummation of the Kintara Merger.

(7)Ms. Favorito served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and ceased serving on the board of directors in connection with the consummation of the Kintara Merger.

(8)We did not make any stock option awards to its directors during the fiscal year ended December 31,2024.

On November 26, 2024, our board of directors approved of a Non-Employee Director Compensation Program (the “Non-Employee Director Compensation Program”), effective beginning January 1, 2025. 

Each of our non-employee directors as of December 31, 2024 held the following outstanding options: 

    Name(1)
     
    Shares Subject to Outstanding Options

    James Manuso, Ph.D
     
    27,106

    Alan List, M.D.
     
    27,106

    George Ng
     
    62,891

(1)Does not include the number of shares subject to outstanding options held by